Targets & Mechanisms
New life for EGFR at ASCO21
ASCO21 abstracts highlight opportunities for new EGFR-targeting agents and combos to fill holes left by TKIs
ASCO21 abstracts highlight opportunities for new EGFR-targeting agents and combos to fill holes left by TKIs.
This year’s ASCO features a series of compounds and combos taking aim at resistance mechanisms plaguing the sea of marketed therapies against EGFR.
The biggest focus is on EGFR-mutant non-small cell lung cancer (NSCLC), an indication where resistance to EGFR-targeting tyrosine kinase inhibitors (TKIs) frequently emerges, and where patients with certain mutations have historically been left behind.
That picture is rapidly changing for NSCLC with rare EGFR exon 20 insertion mutations, which produce a conformational change in the receptor’s intracellular domain that renders tumors insensitive to traditional TKIs.
This NSCLC subset saw its first approval last week — the bispecific antibody Rybrevant